UCB


Management’s guidance upgrade for FY19

13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."

Pages
52
Language
English
Published on
13/01/20
You may also be interested by these reports :
28/01/20
Novozymes reported mixed Q4 19 numbers – missing on topline but beating bottomline estimates. Sales came in at DKK 3,731m, up 1% on an organic basis, ...

24/01/20
As results of a futility analysis indicate that palovarotene’s phase III trial could miss the primary endpoint, Ipsen has suspended the studies ...

24/01/20
Besides lowering our DCF and NAV, we have increased the discount on the peer-based valuations to factor in this disappointing news. Our target price ...

21/01/20
Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO